Table 2.

Cross-sectional correlations between fatigue and patient reported, clinical, laboratory and ultrasound variables at all visits in patients with rheumatoid arthritis initiating biologic DMARDs.

	Baseline, n = 208	1 month, n = 208	2 months, n = 204	3 months, n = 197	6 months, n = 183	12 months, n = 160
Patient’s global VAS	0.73**	0.76**	0.70**	0.70**	0.76**	0.66**
Joint pain VAS	0.64**	0.70**	0.65**	0.63**	0.71**	0.47**
MHAQ	0.62**	0.58**	0.22*	0.48**	0.62**	0.41**
SF36 Mental Health	− 0.56**	− 0.67**	− 0.55**	− 0.58**	− 0.61**	− 0.55**
Pain catastrophizing	0.58**	0.60**	0.52**	0.52**	0.50**	0.42**
28 tender joint count	0.48**	0.50**	0.47**	0.51**	0.54**	0.26*
Examiner’s global VAS	0.28**	0.27**	0.23*	0.29**	0.32**	0.17*
Calprotectin (μg/L)	0.07	0.14*	0.08	0.02	0.18*	0.11
CRP (mg/L)	0.11	0.13	0.09	0.09	0.14	0.02
28 swollen joint count	0.15*	0.08	0.09	0.09	0.10	0.01
Sum score GS	0.02	0.03	0.02	0.02	0.02	0.05
Sum score PD	0.03	0.05	0.01	0.03	0.02	0.01

VAS visual analogue scale, MHAQ modified health assessment questionnaire, SF36 Mental Health short form 36 Mental Health scale score, CRP C-reactive protein, GS grey scale ultrasound, PD power Doppler ultrasound

*p < 0.05, **p < 0.001